0
0
As India continues to grapple with one of the world’s highest burdens of viral hepatitis, a recent analysis of China’s public health strategy offers both a cautionary tale and a clear, evidence-based roadmap. While India has made significant strides in prevention, the experience of its neighbor suggests that moving the needle on this silent epidemic requires more than just high vaccination rates—it demands a total transformation of how we find and treat those already living with the infection.
According to a 2026 report by the World Health Organization (WHO), India remains among a small group of ten countries that together account for 69% of global hepatitis B-related deaths and 58% of hepatitis C-related deaths. With tens of millions of people affected, the path to elimination is a race against time, as these infections often progress silently until they cause irreversible liver damage.
The China Model: A Story of Two Eras
China’s journey against hepatitis B provides a compelling case study. For decades, the country struggled with high infection rates. However, by prioritizing universal infant vaccination, China achieved remarkable success in protecting its youngest generation.
Recent data published in Hepatobiliary Surgery and Nutrition highlights the dramatic impact of these interventions:
-
Vaccination Reach: Three-dose hepatitis B vaccination coverage in China has soared to 99.6%.
-
Birth-Dose Success: Timely administration of the first vaccine dose at birth—a critical step in preventing mother-to-child transmission—reached 95.6%.
-
Generational Shift: The prevalence of hepatitis B surface antigen (a marker of current infection) in children under five plummeted from 9.67% in 1992 to just 0.30% in 2020.
“China shows us that if you get the vaccine into the hands of every newborn, you can effectively stop the new generation from becoming infected,” notes a public health expert familiar with regional epidemiological trends. “But that is only half the battle. The challenge is what to do with the millions of adults who were already infected before these programs were fully implemented.”
The “Hidden Burden” Gap
While China successfully halted new infections in children, the country still carries a heavy load of roughly 75 million people living with chronic hepatitis B. The report reveals a critical bottleneck: while people are being vaccinated, they are not being diagnosed or treated.
In 2020, only about 59% of individuals living with hepatitis B in China were aware of their status, and only 17% of those eligible for life-saving antiviral medication were actually receiving it. This “diagnosis-to-treatment gap” is where India’s greatest challenge—and opportunity—lies.
For India, the lesson is clear: vaccination is the foundation, but screening is the engine of elimination.
Implications for India’s Public Health Strategy
WHO guidance consistently emphasizes that for high-burden countries like India, public health systems must integrate four pillars:
-
Universal Vaccination: Continuing to maintain high coverage for infants.
-
Routine Screening: Incorporating hepatitis testing into standard antenatal care and high-risk settings.
-
Safe Practices: Ensuring rigorous blood screening and the use of sterile, single-use injection equipment.
-
Linkage to Care: Creating clear, affordable referral pathways that move a patient from a positive test result directly to effective, long-term antiviral therapy.
“Many people feel perfectly well for years, even while the liver is undergoing chronic inflammation,” the WHO noted in its 2026 global report. “The silence of the disease is the primary reason it progresses to cirrhosis or liver cancer.”
Medical professionals advise that individuals with specific risk factors—such as a history of blood transfusions prior to modern screening, dialysis, use of non-sterile needles, or maternal exposure—should proactively discuss hepatitis testing with their healthcare provider.
Caution and Context
While the comparison between the two nations is valuable, experts warn against a “copy-paste” approach to policy. Health system design, financial resources, and regional disease patterns vary significantly between China and India. Furthermore, statistics on hepatitis burden can fluctuate based on the methods used to estimate them.
“We cannot expect one country’s policy to work perfectly in another,” says a clinical specialist. “The real takeaway is methodological. We must accurately measure the specific burden in our own regions, screen widely, and ensure that once we find a case, we don’t just record it—we treat it.”
For the average citizen, the message is one of cautious optimism: hepatitis B and C are often preventable, and in the case of hepatitis C, frequently curable with short-course therapy. By shifting the focus from viewing hepatitis solely as a vaccination challenge to treating it as a chronic, manageable, and screenable health condition, India has the potential to save millions of lives over the coming decade.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
India Today Insight. How China’s hepatitis burden is a lesson for India’s public health system. Published July 18, 2026.
